191934-25-5

Upstream product

• 150-13-0 4-amino-benzoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 66493-39-8 4-(N-tert-butoxycarbonyl)aminobenzoic acid 
• 100-39-0 benzyl bromide 

Downstream Products

• 19008-43-6 benzyl 4-aminobenzoate 
• 1357620-24-6 4-(2-(diethylamino)acetamido)-N-(4-nitrophenyl)benzamide 
• 903302-05-6 N-(4-methoxyphenyl)-4-(2-(piperidin-1-yl)acetamido)benzamide 
• 1357620-21-3 3-acetamido-N-(4-(2-(diethylamino)acetamido)phenyl)benzamide 
• 1357620-09-7 4-(4-morpholinobutanamido)benzoic acid 
• 751479-06-8 4-(4-(dimethylamino)butanamido)benzoic acid 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of 4′-demethyl-4-deoxypodophyllotoxin derivatives as novel tubulin and histone deacetylase dual inhibitors

A new class of 4′-demethyl-4-deoxypodophyllotoxin derivatives has been designed and synthesized as tubulin-HDAC dual inhibitors. Biological evaluation of these hybrids included the inhibitory activity of HDAC, in vitro cell cycle analysis in HCT-116 cells as well as cytotoxicity against two cancer cell lines (A549 and HCT116). The distance and angle between the HDAC capping group and the zinc binding group were systematically varied. Compounds 14a and 14c showed most potent dual inhibitory activity and powerful antiproliferative activity on HCT116 and A549 cell lines. This journal is

Synthesis of benzoic acids and polybenzamides containing tertiary alkylamino functionality

The high-yielding and easily scalable synthesis of a number of benzoic acids bearing a tertiary alkylamino functionality has been achieved. The flexible synthesis began from readily available aminobenzoic acids or terephthaloyl chloride and requires almost no chromatography. Coupling of the synthesised amino acids to a range of substituted anilines was achieved when utilizing a specific combination of DIC, HOBt and DMAP.

Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship

Based on structure-activity relationship studies, we designed and synthesized plasmin (PL) and plasma kallikrein (PK) inhibitors. Trans-(4-aminomethylcyclohexanecarbonyl)-Tyr(O-PIC)-octylamide inhibited PL, PK, urokinase (UK) and thrombin (TH) with IC50 values of 0.53, 30, 5.3 and >400 μM, respectively. Trans-(4-aminomethylcyclohexanecarbonyl)-Tyr(O-2-Pyrim)-4-carboxyanilide inhibited PL, PK, UK and TH with IC50 values of 36, 0.56, 440 and >1000 μM, respectively.